Exclusive: China in talks with Pfizer for generic COVID drug
/cloudfront-us-east-2.images.arcpublishing.com/reuters/M5NT4EWIONOTLGJVNI7FXCLVDQ.jpg?fit=%2C&ssl=1)
HONG KONG/BEIJING, Jan 6 (Reuters) – China is in talks with Pfizer Inc (PFE.N) to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of the US firm’s COVID-19 antiviral drug Paxlovid in China, three sources told Reuters. China’s medical products regulator – the National Medical Products Administration (NMPA) … Read more